Search Results - "Elkrief, A."

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? by Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., Routy, B.

“…Immune-checkpoint inhibitors (ICI) now represent the standard of care for several cancer types. In pre-clinical models, absence of an intact gut microbiome…”
Get full text

Molecular targets and novel therapeutic avenues in soft-tissue sarcoma by Elkrief, A, Alcindor, T

“…Soft-tissue sarcoma (sts) represents a heterogeneous group of rare tumours, and a significant number of affected patients will develop metastatic disease…”
Get full text

Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020 by Elkrief, A, Joubert, P, Florescu, M, Tehfe, M, Blais, N, Routy, B

“…Lung cancer is the most commonly diagnosed cancer in Canada and remains associated with high mortality. Nevertheless, recent advances in the fields of…”
Get full text

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer by Ricciuti, B., Alessi, J.V., Elkrief, A., Wang, X., Cortellini, A., Li, Y.Y., Vaz, V.R., Gupta, H., Pecci, F., Barrichello, A., Lamberti, G., Nguyen, T., Lindsay, J., Sharma, B., Felt, K., Rodig, S.J., Nishino, M., Sholl, L.M., Barbie, D.A., Negrao, M.V., Zhang, J., Cherniack, A.D., Heymach, J.V., Meyerson, M., Ambrogio, C., Jänne, P.A., Arbour, K.C., Pinato, D.J., Skoulidis, F., Schoenfeld, A.J., Awad, M.M., Luo, J.

“…Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASMUT) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous…”
Get full text

Erratum: Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020 by Elkrief, A, Joubert, P, Florescu, M, Tehfe, M, Blais, N, Routy, B

“…In Table i in the initially published manuscript, several column headings are incorrectly presented.[...]…”
Get full text

1054P Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer by Elkrief, A., Bowman, A., Rizvi, H., Hellmann, M., Riely, G.J., Schoenfeld, A.J., Ladanyi, M., Vanderbilt, C.M.

Get full text

Molecular targets and novel therapeutic avenues in soft tissue sarcoma by Elkrief, A., Alcindor, T.

Get full text

CN12 Impact of diet on immune checkpoint blockade: Nurse-directed dietary intervention by Malo, J., Benlaïfaoui, M., Diop, K., Messaoudene, M., Belkaid, W., Elkrief, A., Blais, N., Tehfe, M., Florescu, M., Al-Saleh, A., Leblanc, A., Marcil, V., Routy, B., Richard, C.

Get full text

1394P Deep learning model to predict clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors by Elkrief, A., Phan, K., Di Jorio, L., Simpson, R., Chassé, M., Malo, J., Richard, C., Kosyakov, M., Chandelier, F., Kafi, K., Routy, B.

Get full text

1357P A deep radiomics approach to assess PD-L1 expression and clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A multicentric study by Tonneau, M., Phan, K., Kazandjian, S., Elkrief, A., Panasci, J., Richard, C., Nolin-Lapalme, A., El Sayed, R., Ding, L., Nair, T., Malo, J., Chandelier, F., Kafi, K., O'Brien, J., Di Jorio, L., Muanza, T., Routy, B.

Get full text

LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis by Wise-Draper, T.M., Desai, A., Elkrief, A., Rini, B.I., Flora, D.B., Bowles, D.W., Shah, D., Rivera, D., Johnson, D.B., Lopes, G., Grivas, P., Thompson, M.A., Peters, S., Kuderer, N.M., Nock, N.L., Grover, P., Li, X., Gulati, S., Choueiri, T.K., Warner, J.

Get full text

Cancer patient participation and compliance in microbiome sample collection: An oncology research nurse’s experience by Malo, J., Messaoudene, M., Cauchois, F., Belkaid, W., Frizon-Peresa, D., Ikene, S., Rousseau, L., Lattouf, J.-B., Elkrief, A., Mezquita, L., Derosa, L., Besse, B., Blais, N., Alameddine, R., Tehfe, M., Florescu, M., Routy, B.

Get full text

CN111 - Cancer patient participation and compliance in microbiome sample collection: An oncology research nurse’s experience by Malo, J., Messaoudene, M., Cauchois, F., Belkaid, W., Frizon-Peresa, D., Ikene, S., Rousseau, L., Lattouf, J.-B., Elkrief, A., Mezquita, L., Derosa, L., Besse, B., Blais, N., Alameddine, R., Tehfe, M., Florescu, M., Routy, B.

“…Several lines of evidence suggest that the gut microbiome represents a novel biomarker in the era of immuno-oncology. Therefore, the prospective collection of…”
Get full text

CN111Cancer patient participation and compliance in microbiome sample collection: An oncology research nurse’s experience by Malo, J, Messaoudene, M, Cauchois, F, Belkaid, W, Frizon-Peresa, D, Ikene, S, Rousseau, L, Lattouf, J-B, Elkrief, A, Mezquita, L, Derosa, L, Besse, B, Blais, N, Alameddine, R, Tehfe, M, Florescu, M, Routy, B

“…Abstract Background Several lines of evidence suggest that the gut microbiome represents a novel biomarker in the era of immuno-oncology. Therefore, the…”
Get full text

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? by Elkrief, A, Derosa, L, Kroemer, G, Zitvogel, L, Routy, B

“…Immune-checkpoint inhibitors (ICI) now represent the standard of care for several cancer types. In pre-clinical models, absence of an intact gut microbiome…”
Get full text

229P Clinicopathologic and genomic features of patients with mucinous lung adenocarcinoma and response to systemic therapies by Di Federico, A., Hong, L., Elkrief, A., Thummalapalli, R., Ricciuti, B., Alessi, J., Gogia, P., Pecci, F., Gandhi, M., Ladanyi, M., Zhang, J., Gibbons, D., Heymach, J., Nishino, M., Sholl, L., Awad, M., Arbour, K.C., Schoenfeld, A., Vokes, N., Luo, J.

Get full text

73P Correlation between diet, microbiome composition and clinical outcomes in patients with non-small cell lung cancer by Malo, J., Benlaïfaoui, M., Lehoux-Dubois, C., Salazar, E. Mendez, Diop, K., Ponce, M., Kourtian, S., Maillou, J., Moreau-Amaru, D., Duttagupta, S., Belkaid, W., Blais, N., Tehfe, M., Florescu, M., Elkrief, A., Messaoudene, M., Marcil, V., Routy, B.

Get full text

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS G12D -mutated non-small-cell lung cancer by Ricciuti, B, Alessi, J V, Elkrief, A, Wang, X, Cortellini, A, Li, Y Y, Vaz, V R, Gupta, H, Pecci, F, Barrichello, A, Lamberti, G, Nguyen, T, Lindsay, J, Sharma, B, Felt, K, Rodig, S J, Nishino, M, Sholl, L M, Barbie, D A, Negrao, M V, Zhang, J, Cherniack, A D, Heymach, J V, Meyerson, M, Ambrogio, C, Jänne, P A, Arbour, K C, Pinato, D J, Skoulidis, F, Schoenfeld, A J, Awad, M M, Luo, J

“…Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRAS ) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous…”
Get full text